2054. Hypertesion Control:  How Well Are We Doing?
AM Borzecki, CHQOER, Bedford VAMC, and Boston University School of Public Health, AT Wong, CHQOER, Bedford VAMC, and Boston University School of Public Health, EC Hickey, CHQOER, Bedford VAMC, and Boston University School of Public Health, AS Ash, Section of General Internal Medicine, Boston Medical Center and Boston University School of Medicine, DR Berlowitz, CHQOER, Bedford VAMC, and Boston University School of Public Health, Section of General Internal Medicine, Boston Medical Center and Boston University School of Medicine

Objectives: We previously documented that over 65% of hypertensive veterans had poorly controlled blood pressure (BP) and poor control was associated with providers being under-aggressive in increasing antihypertensive medications. Since then the VA has devoted considerable resources toward improving care. The current study determined BP control in a recent cohort of hypertensive veterans; compared this to the previous cohort and examined whether hypertension treatment practices, defined by the frequency of antihypertensive medication increases, have changed over time.

Methods: We abstracted 1999 outpatient chart data including visit type, BP, comorbidities, and medications for 981 randomly selected hypertensive veterans at 10 VA sites.  We examined BP control overall, in subgroups with diabetes and renal disease, and compared control with a previously studied sample of 800 veterans from 1990-1995. Lastly, we compared the frequency of antihypertensive medication increases in the two samples, accounting for current BP levels, and other factors associated with therapy increases.

Results: Mean BPs were significantly lower in 1999 versus ‘90-‘95; the mean systolic drop was 3.1 and reached 13.7 mm Hg for those with both diabetes and renal disease. Larger decreases were seen in mean diastolic BPs.  In 1999, 57% had a BP >=140/90 versus 69% in ‘90-‘95 (p<0.0001). In 1999, diabetics had analogous control to non-diabetics with 60% >=140/90; renal disease patients had better control than those without; 43% versus 58% >=140/90 (p=0.01).  Patients with diabetes, renal disease or both had better control in 1999 than in ‘90-‘95, (p<0.0001 in all cases).  More 1999 visits were associated with medication increases compared to ‘90-‘95 both overall (25% versus 11%) and when considering specific factors associated with increases.

Conclusions: BP control has improved in the VA both overall and in patients with diabetes and renal disease. This is likely due to more aggressive treatment.  However, most patients still exceed recommended levels and diabetics had similar control to non-diabetics, rather than guideline-recommended tighter control.

Impact: VA hypertension quality improvement efforts have had an impact, although still more attention needs to be devoted to improving care especially in subgroups with diabetes and renal disease where treatment can have significant benefit in reducing morbidity and mortality.